FLT3 and acute myeloid leukemia: Moreover lack of sensitization of remission bone marrow cells may predict that concurrent treatment with Pim kinase and topoisomerase 2 inhibitors in the clinical setting will be associated with a favorable therapeutic index for FLT3-ITD AML cells in relation to normal hematopoietic cells.